Innoviva (INVA) Receivables - Net (2013 - 2026)
Innoviva (INVA) reported Receivables - Net of $34.0 million for Q1 2026, up 103.95% on a YoY basis from $16.7 million in Q1 2025, and down 2.75% quarter-over-quarter from $35.0 million in Q4 2025.
Innoviva (INVA) Receivables - Net (2013 - 2026) Analysis & Trends
Innoviva has reported Receivables - Net for 7 years, with the latest figure at $34.0 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Net rose 103.95% year-over-year to $34.0 million; the trailing twelve-month figure through Mar 2026 stood at $34.0 million (up 103.95% YoY), and the FY2025 full-year result was $35.0 million, up 71.47% from the prior year.
- Receivables - Net for Q1 2026 stood at $34.0 million, down from $35.0 million in the prior quarter.
- The five-year high for Receivables - Net was $35.0 million in Q4 2025, with the low at $6.7 million in Q3 2022.
- Historically, Receivables - Net has averaged $20.0 million across 5 years, with a median of $16.7 million in 2025.
- Annual changes were most pronounced in 2024 — Receivables - Net soared 184.1% — and 2025, when it dropped 21.87%.
- Innoviva's Receivables - Net stood at $9.4 million in 2022, then surged by 53.75% to $14.5 million in 2023, then surged by 41.08% to $20.4 million in 2024, then surged by 71.47% to $35.0 million in 2025, then slipped by 2.75% to $34.0 million in 2026.
- The last three Receivables - Net figures came in at $34.0 million (Q1 2026), $35.0 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Innoviva | 1.66 Bn | 1.05 Bn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.01 Mn |
| Mar 31, 2026 | 34.01 Mn |
| Dec 31, 2025 | 34.97 Mn |
| Dec 31, 2025 | 34.97 Mn |
| Sep 30, 2025 | 30.17 Mn |
| Sep 30, 2025 | 30.17 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Jun 30, 2025 | 20.93 Mn |
| Mar 31, 2025 | 16.67 Mn |
| Mar 31, 2025 | 16.67 Mn |
| Dec 31, 2024 | 20.39 Mn |
| Dec 31, 2024 | 20.39 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 26.78 Mn |
| Jun 30, 2024 | 26.78 Mn |
| Mar 31, 2024 | 14.14 Mn |
| Mar 31, 2024 | 14.14 Mn |
| Dec 31, 2023 | 14.45 Mn |
| Dec 31, 2023 | 14.45 Mn |